title: Update on massive transfusion.
abstract: Massive haemorrhage requires massive transfusion (MT) to maintain adequate circulation and haemostasis. For optimal management of massively bleeding patients, regardless of aetiology (trauma, obstetrical, surgical), effective preparation and communication between transfusion and other laboratory services and clinical teams are essential. A well-defined MT protocol is a valuable tool to delineate how blood products are ordered, prepared, and delivered; determine laboratory algorithms to use as transfusion guidelines; and outline duties and facilitate communication between involved personnel. In MT patients, it is crucial to practice damage control resuscitation and to administer blood products early in the resuscitation. Trauma patients are often admitted with early trauma-induced coagulopathy (ETIC), which is associated with mortality; the aetiology of ETIC is likely multifactorial. Current data support that trauma patients treated with higher ratios of plasma and platelet to red blood cell transfusions have improved outcomes, but further clinical investigation is needed. Additionally, tranexamic acid has been shown to decrease the mortality in trauma patients requiring MT. Greater use of cryoprecipitate or fibrinogen concentrate might be beneficial in MT patients from obstetrical causes. The risks and benefits for other therapies (prothrombin complex concentrate, recombinant activated factor VII, or whole blood) are not clearly defined in MT patients. Throughout the resuscitation, the patient should be closely monitored and both metabolic and coagulation abnormalities corrected. Further studies are needed to clarify the optimal ratios of blood products, treatment based on underlying clinical disorder, use of alternative therapies, and integration of laboratory testing results in the management of massively bleeding patients.
authors: New York Blood Center, New York, NY, USA.
authors: H P
authors: HP
authors: Pham
authors: B H
authors: BH
authors: Shaz
mesh_terms: D001778:Blood Coagulation Disorders / Q000209:etiology; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D001803:Blood Transfusion; D006470:Hemorrhage / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D013916:Thrombelastography; D014148:Tranexamic Acid / Q000627:therapeutic use
chemical_list: D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D014148:Tranexamic Acid
keywords: massive transfusion; massive transfusion protocol; paediatric transfusion protocol; transfusion management